FDA Clears Tandem's Control-IQ+ for Pregnant Type 1 Diabetics
TNDM has more than doubled off its 52-week low of $9.98.
Summary
Tandem Diabetes Care has secured FDA clearance for its Control-IQ+ automated insulin delivery technology for use in pregnant individuals with Type 1 diabetes. This regulatory approval is a significant positive development, expanding the addressable market for Tandem's key product to a sensitive and previously underserved patient population. The clearance validates the safety and efficacy of Control-IQ+ for managing blood glucose during pregnancy, a period requiring stringent glycemic control. This move is expected to drive increased adoption and potential revenue growth for the company, building on its strong 2025 sales performance. Investors will now monitor the commercial rollout and uptake rates within this new indication.
At the time of this announcement, TNDM was trading at $20.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.98 to $29.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.